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Summary 
The Wiskott-Aldrich syndrome (WAS) is a severe  immunodeficiency  and platelet deficiency disease 
arising from an X-linked defect. The disease is correctable by transplantation of hematopoietic 
stem cells, but the product of the defective gene is unidentified and the number of defects in 
patient blood cells is large. The current hurdle is the need to identify the early pathogenic event(s) 
that are the cause of other defects. As a step toward this goal, we have generated and examined 
a panel of interleukin 2-dependent allospecific T cell lines from peripheral lymphocytes of seven 
WAS patients and five normal individuals. WAS cell lines, like normal lines, undergo vigorous 
proliferation when challenged with specific allostimulant or with phorbol myristate acetate and 
ionomycin. Both normal and WAS T  cell lines express cell surface molecules CD2, CD3, T 
cell receptor-cff~ human histocompatibility leukocyte antigen class I, CD45 and CD11a,  and 
varying ratios of CD4 and CD8, and are negative for natural killer cell and monocyte surface 
molecules. WAS T cell lines express CD43 (sialophorin/leukosialin) with molecular weight and 
in an amount comparable with normal T cell lines. WAS T cell lines thus do not express defects 
in CD43  (decreased  amount, abnormal molecular weight), previously documented in WAS 
circulating lymphocytes. On the other hand, as detected by scanning electron microscopy, WAS 
cell lines exhibit severe morphological abnormalities, including decreased size and density of the 
microvillus surface projections. The morphological abnormalities of WAS T cell lines are similar 
to, or more extensive than, those previously reported for WAS peripheral lymphocytes, indicating 
that the generation of morphological (cytoarchitectural)  defects is an early pathogenic event in 
this disease. The findings suggest that the gene that is defective in the WAS encodes a protein 
that normally functions to maintain or regulate the cytoskeletal  structure of blood cells. 
T 
he Wiskott-Aldrich syndrome (WAS) 1 is an X-linked 
disorder involving severe deficiency of platelet and im- 
munologic function (1-3).  The number of documented ab- 
normalities in the disease is very large, and, since the product 
of the defective X-chromosome gene is unidentified, the cur- 
rent challenge is to establish chronology of the pathological 
events that result from the primary genetic defect. 
Among the most dramatic defects associated with the WAS 
are  the severely decreased  size and number of circulating 
platelets thought to be caused by destructive processes (4). 
Defects of T lymphocytes, the most definitively involved leu- 
kocytes, include abnormal cell surface morphology (cytoar- 
chitecture), documented  by scanning electron microscopy and 
characterized by the paucity of the microvillus surface projec- 
tions found on normal blood lymphocytes (5). At the too- 
1 Abbreviation  used in  this paper: WAS, Wiskott-Aldrich syndrome. 
lecular level, defects of WAS T lymphocytes include the reduc- 
tion in quantity, and in some cases, abnormal molecular weight 
of the cell surface glycoprotein molecule CD43 (formerly 
sialophorin or leukosialin) (6-10). CD43 was excluded as the 
possible primary defect because it is encoded by an autosomal 
gene (11, 12). Other molecular defects of WAS blood cells 
include abnormalities of the T  lymphocyte enzymes that 
glycosylate CD43 (9, 10). Further molecular defects include 
abnormalities of Ca  2+ regulated neutral protease (calpain) of 
WAS platelets  (Kenney, D. M., F. S. Rosen, R. Reid, and 
E. Remold O'Donnell, manuscript in preparation). 
In an effort to identify early pathological events in WAS, 
we have established and characterized long-term T cell lines 
from affected males. The patient T cell lines should, in theory, 
be an excellent experimental system for studying early patho- 
logical events in the disease. The cell lines are expected to 
express the inherited defective gene and the directly resultant 
defective product(s), but on the other hand, should be free 
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tion. This prediction is demonstrated here by the finding that 
the long-term T  cell lines from WAS patients express one 
defect previously associated with WAS blood lymphocytes, 
but lack another defect, which therefore likely results from 
secondary interactions of circulating blood cells. 
Materials and Methods 
Patients.  The diagnosis of WAS was based on male sex, severe 
thrombocytopenia with platelets of reduced size and, in some pa- 
tients, a positive family history. The patients had eczema and/or 
immunodeficiency.  None was splenectomized. The clinical profile 
of  the patients is summarized in Table 1. Platelet size was measured 
as effective  mean diameter using an electronic particle analyzer (El- 
zone Model 112; Particle Data Inc., Elmhurst, IL) calibrated with 
2.02 # htex beads (Coulter Electrouics, Inc., Hialeah, FL). 
Generaa'on of Allospecific T CelI Lines.  Patient  and normal whole 
blood anticoagnlated  with National Institutes of  Health (NIH) for- 
mula A add-citrate-dextrose, either freshly drawn or after over- 
night shipment at ambient temperature, was centrifuged at 150 g, 
and the phtelet-rich plasma was removed. All blood cell isolation 
was performed at room temperature in plastic or siliconized  glass. 
The packed cells were diluted with an equal volume of Ca  2+ / 
Mg  z+  free HBSS (Whittaker  Bioproducts, Walkersville, MD), 
layered  onto Histopaque 1077 (Sigma  Chemical  Co., St. Louis,  MO), 
and centrifuged at 800 g for 40 rain. The interface mononudear 
cells were washed three times in PBS and were cocultured at 0.5:1 
stimulator to responder ratio with the class II + B-lymphoblastoid 
cell line Kaji, which had been pretreated with mitomycin C (13). 
The culture medium was R.PM11640 (Mediatech, Inc., Washington, 
DC) with 10% FCS (HyClone Laboratories, Inc., Logan, UT), 
10% conditioned media from normal blood mononuclear cells  cul- 
tured at 10~/ml  with 2 #g/m1 of PHA (Sigma Chemical Co.) for 
48 h (14), and 40 U/ml of rIL-2 (prepared by Hoffman-LaKoche, 
Nutley, NJ, and obtained  through the Biological  Response  Modifiers 
Program of the National Cancer Institute) as the source of lym- 
phokines and growth factors. The cells were stimulated as above 
every 7 d. They were expanded, and fresh supplement was added 
as needed (usually every 3 d). The cell lines have been maintained 
in continuous culture for a minimum of 3 mo and are considered 
established since they have stable  phenotype and growth properties. 
Proliferative Assays.  T cells were harvested 10 d after allospecific 
stimulation. The cells were washed and plated at 2  x  10Vwell 
in 96-well plates, and cocultured at 1:1, 0.5:1, and 0.25:1 stimu- 
lator to responder ratio with mitomycin C pretreated class II § 
stimulator lines U937 (monocytic lcukemia) (15) or SPB-10 cells 
(EBV-transformed normal B cells provided by Jerrold Schwaber, 
Hahnemann University, Philadelphia, PA). Alternatively, the cell 
lines were stimulated with 5 ug/ml of  PMA (Sigma  Chemical Co.), 
with or without 0.1, 0.2, or 0.5 #g/ml of ionomycin (Calbiochem 
Corp., La Jolla, CA). After 48 h, 1 #Ci/well of [3H]thymidine 
(New England Nuclear, Boston, MA) was added, and the cells  were 
cultured for an additional 16 h, harvested onto glass fiber paper 
(Cambridge Technologies, Waltham, MA), and [3H]thymidine  in- 
corporation was quantified by liquid scintillation counting. 
Antibodies.  mAbs OKT3  (anti-CD3),  OKT4  (anti-CD4), 
OKT8 (anti-CD8), OKM-1 (anti-CDllb) (16), OKTll (anti-CD2), 
GAP8.3 (anti-CD45) (17), and W6/32 (anti-HI, A-class I) (18) were 
obtained from the American Type Culture Collection (Rockville, 
MD). Anti-CD43 mAbs L10 (7) and Lll (4) were generated in 
this laboratory. The mAb T305 (19) provided by Dr. K. I. Fox 
(Scripps Clinic, La Jolla, CA) is an IgG1 that recognizes a tool 
wt  125,000 isoform of CD43  found on activated lymphocytes 
(19-22). The anti-CD11a TA-1 mAb (23) was provided by Dr. T. 
LeBien (University of Minnesota, Minneapolis). The anti-CD16 
(24) 3G8  mAb  was provided by Dr. J.  Unkdess  (Rockefeller 
University, New York). The anti-CD43 mAb DF-T1 (25), and the 
anti-CD25 (IL-2R) Act-1 mAb were from Dakopatts (Glostrup, 
Denmark). The anti-ot/B TCR WT31 mAb (26) was from Becton 
Dickinson (Mountain View, CA). FITC-labded F(ab')2 goat anti- 
mouse IgG was from Tago, Inc. (Burliugame, CA). 
Sialidase Treatment.  T cell lines were washed and incubated in 
RPMI 1640 at room temperature with 0.01 U/ml/106 cells of siali- 
dase from Vibn'o cholera (Calbiochem Corp.) for 30 min and then 
washed. The cells were stained with mAb before and immediately 
after sialidase  treatment, and after additional 18 h culture in serum- 
containing media. 
Flow Cytometric Analysis.  Cells  (5  x  106) were incubated with 
mAb for 30 min on ice, washed, arid incubated with FITC labeled 
F(ab')2 goat anti-mouse  IgG (4). The cells were washed, fixed, 
and analyzed on an Epics V cytofluorograph (provided through 
the courtesy of Wallace H. Coulter, Coulter  Electronics, Inc., 
Hialeah FL). 
Western Blots.  Cells  were lysed  in buffer containing 0.5% NP-40 
and clarified  by centrifugation as described (4). The proteins were 
separated by SDS-PAGE (7.5% polyacrylamide)  and electroblotted 
onto nitrocellulose (4) (Schleicher & Schuell, Inc., Keene, NH). 
The blots were stained as described (4) with mAb followed  by bio- 
tinylated second  antibody and a preincubated  mixture of  avidin and 
biotinylated horseradish peroxidase reagents (Vector Laboratories, 
Inc., Burlingame, CA). 
Scanning Electron Microscopy.  Cells  (2-5  x  106) from prolifer- 
ating or resting cultures (3 and 10 d after allospecific  stimulation, 
respectively) were washed in Ca  2+/Mg  2+ free HBSS (Whittaker 
Bioproducts), and equilibrated at 37~  for 30 min. The cells were 
fixed as described (5) in 1.25% glutaraldehyde  for 1 h at 370C and 
14 h at 4~  collected  on polyrarbonate  membranes (0.4 #) (Nudeo- 
pore Corp., Pleasanton,  CA), and postfaxed  in 1% osmium tetroxide 
for 1 h. Subsequently,  cells were dehydrated with graded ethanols, 
subjected to critical point drying from carbon dioxide, coated with 
gold/palladium (60:40), and examined on a scanning dectron mi- 
croscope (Model DS130; International Scientific  Instruments, Santa 
Clara, CA). For each sample, ceils  in randomly selected fields  were 
photographed at a magnification of 2,500-6,700. 
Results 
Establishment  ofT CellLines.  T cell lines were established 
from peripheral lymphocytes of seven WAS patients (Table 
1) and five normal individuals by stimuhtion with Raji cells. 
No subfractionation of  peripheral mononuclear cells was per- 
formed before stimulation so as to obtain lines representative 
of circulating ceils. The T cell lines are dependent for long- 
term growth on weekly stimulation and addition of growth 
factors.  No cases of spontaneous transformation have been 
observed. 
Pkenotypic Characterization  of T  Cell Lines.  The patient 
and normal cell lines are >95% positive for T cell molecules 
CD2 and CD3, as assessed by flow cytometry (Fig. 1) as well 
as the TCK-ot/B (Table 2). Both patient and normal ceil lines 
exhibit a heterogeneous distribution of CD4 and CD8 mol- 
ecules (Fig.  1), and are negative for the monocyte and NK 
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Patient  Age 
Platelet  Mean  Intravenous 
count/#l  plateht  gammaglobulin Family 
whole blood  diameter  therapy  history 
P1  1.6 yr  32,500  1.87  +  - 
P2  31  yr  26,600  1.95  -  + 
P3*  9  mo  141,000  1.90  +  - 
P4  27 yr  33,200  1.92  -  + 
P5  29 yr  29,800  1.91  -  + 
P6  14 yr  40,900  1.89  +  + 
P7  12  yr  13,200  1.90  +  + 
N*  290,000  2.29 
(•  65,000) (•  0.12) 
* Whole blood platelet count on patient P3 subsequently  decreased to 
20,000. 
* Mean whole blood platelet count and mean plateht diameter + SEM 
obtained for 26 normal donors using the equipment and procedures ap- 
plied to the patient samples. 
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Figure 1.  How cytometric  characterization  ofT cell  lines  from  normal 
individuals and WAS patients. Panels from  left to right show T cell lines 
stained  with an isotype-matched  irrelevant  control  mAb, and mAbs defining 
CD2, CD3, CD4, and CD8. Graphs represent cell number versus loga- 
rithm of fluorescence  intensity. (NI-N4)  T cell lines derived  from lym- 
phocytes of four normal individuals; (P/-P7) T cell lines derived from 
blood lymphocytes  of the correspondingly  numbered WAS patients de- 
scribed in Table 1. N5 cells analyzed  in other experiments and not shown 
are very similar to lines P1 and P7. 
Table  2.  Flow Cytoraetric Analysis of Patient and 
Normal T  Cell Lines 
Percent of cells positive for indicated antigen" 
Cell  HLA 
line  class I  CD11a  TCIbcdB  CD54  CD56  CD16  CD11b 
N3  96  92  96  33  3  3  3 
P4  92  97  96  41  3  3  3 
P5  94  98  97  49  5  5  4 
* Patient and normal  cell lines were harvested 10 d after  allospecific  stimu- 
lation and stained  with mAbs as indicated  in Materials  and Methods.  The 
mean intensity  of fluorescence for each antigen was similar in normal 
and patient cell lines. 
surface molecules CD11b,  CD16, and CD56 (Table 2).  Pa- 
tient and normal cell lines are >95% positive for class I MHC 
molecules and CDlla (LFA-1) (Table 2). 
Proliferative Responses of T  Cell Lines.  Both patient and 
normal cell lines proliferate vigorously in response to the al- 
lostimulant Raji cells, whereas only minimal proliferation was 
detected when nonallospecific dass II positive U937 or SPB-10 
cells were used (Table 3). Significant proliferation is also in- 
duced by PMA plus ionomycin (Table 3), but not by PMA 
alone (data not shown). Both normal and patient cell lines 
proliferate moderately in the presence of rib2 (Table 3), and 
proliferative responses to various stimuli are enhanced in the 
presence  of rib2 (not shown). 
CD43 Expression on T Cell Lines.  Patient and normal cell 
lines exhibit comparable high expression of CD43 molecules, 
as assessed  by flow cytometry  with the mAb L10, which recog- 
nizes all CD43 isoforms (Fig. 2). No significant differences 
were found in the expression  of the high molecular weight 
CD43 isoform recognized by T305 mAb (19, 20) (Fig.  2). 
In addition, PHA-stimulated lines initiated from two WAS 
patients and maintained in culture for 6 wk also had normal 
surface density of CD43, as assessed by flow cytometry (not 
shown). 
When examined by Western blots stained with L10 mAb, 
CD43 was detected as a broad band of apparent mol wt of 
approximately 135,000  in lysates of both normal cell lines 
(Fig. 3, two left lanes) and WAS cell lines (three fight lanes). 
No obvious difference in CD43 quantity was detected be- 
tween the patient and the normal cell lines. No CD43 degra- 
dation products were observed in the patient cell lines,  in- 
cluding the 95,000  mol wt L10 mAb positive degradation 
product previously found on lymphocytes  isolated from stored 
WAS blood (8).  CD43 was also detected in Western blots 
stained with the T305 mAb, which recognizes higher mo- 
lecular weight CD43 isoforms, and its apparent molecular 
weight (approximately 135,000) was the same in WAS and 
normal cell lines (not shown). 
CD43 was also examined after sialidase treatment of the 
T cell lines by the use of several anti-CD43 mAbs recognizing 
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[3H]Thymidine incorporation in response  to indicated  stimulating  agent 
Cell 
line  None  Raji  U937  SPB-10  PMA  +  ionomycin  rlL-2 
cpra 
N1  540"  164,400"  ND  ND  60,500s  61,100" 
N2  1,100"  178,800"  4,50011  ND  ND  46,600* 
N3  1,000,  86,300*  2,20011  8,50(0  ND  17,900' 
N5  2,200*  46,600*  ND  ND  ND  48,300~ 
P 1  3,400  s  41,400s  ND  ND  51,900s  23,100s 
P2  800*  106,800"  2,10011  3,6001  63,800s  34,200* 
P3  600 *  31,900*  ND  ND  ND  20,100 * 
P4  1,300"  139,600"  ND  4,000~  ND  40,000* 
P5  500*  108,200"  ND  4,100~  ND  14,500" 
P6  1,600"  114,100"  2,20011  5,000~  ND  32,100" 
P7  1,100"*  110,000"*  ND  ND  79,000* *  71,200"* 
Results from different experiments are shown. Individual experiments are identified by footnote symbols. Proliferation assays were performed as 
described in Materials and Methods. 
sialylation-dependent or -independent epitopes. Staining with 
Lll mAb, which is specific  for desialylated CD43 (4), is nega- 
tive in untreated cells (Fig. 4). After sialidase treatment, the 
cells become Lll positive, and the strong staining of untreated 
NIL  I 






cells with the sialylation-dependent anti-CD43 mAbs DF-T1 
and T305  is lost.  The profiles obtained with L10 mAb are 
not changed by sialidase treatment, nor are the profiles ob- 
tained with GAP8.3 mAb, which recognizes CD45, another 
heavily glycosylated molecule. After overnight culture,  the 
CD43 epitopes recognized by DF-T1 and T305 mAbs are re- 
expressed, albeit at lower density, whereas the staining with 
Lll  mAb is  significantly diminished. Thus,  although the 
mechanisms leading to restoration of sialylated CD43 have 
not been clarified, these mechanisms function in an indistin- 
guishable  manner in WAS and normal cell lines. 
Upregulation of T  Cell Activation Molecules during Prolifera- 
tion.  Resting and aUoactivated cell lines were analyzed by 
flow cytometry for expression of activation-associated mole- 
cules.  The ~/chain  of the  II,2  receptor  (CD25)  and the 
Figure 2.  Flow cytometric measurement of CD43 on T cell lines from 
normal individuals (N1-N4) and WAS patients (H-P7). Panels from left 
to right show cells stained with isotype-matched  irrelevant control mAb, 
LIO mAb, which recognizes  all CD43 isoforms, and T305, which recog- 
nizes only high molecular weight CD43 isoforms. 
Figure 3.  Western blot of NP-40 lysates of normal T cell lines N3 and 
N5 and WAS patient cell lines Pl, P4, PS, and P7 stained with L10 mAb. 
Similar results were obtained for the lines N2, N4, P2, and P6. 
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Figure 4.  Restoration of sialylation  of normal (N3) and WAS (P4 and 
PS) T call  lines. Calls were stained  with mAb and analyzed  by flow cytom- 
etry before, or immediately after ( + S'ase), treatment of cells with siali- 
dase, or after an 18-h posttreatment culture under normal culture condi- 
tion ( + S'ase,  O/N). L10 mAb recognizes  a sialic acid-independent  CD43 
epitope; DF-T1 and T305 mAb recognize  sialyhtion-dependent  CD43 epi- 
topes; and Lll recognizes  an epitope of desialylated  CD43 (see Materials 
and Methods). Similar results were obtained with N4 and P6 cells. 
activation-associated epitope of CD43 recognized by the T305 
mAb (22) are upregulated in WAS patient and normal T  cell 
lines when examined on the third day of allostimulation, the 
time of peak proliferation, with no detectable differences in 
patient  and  normal cells  (Fig.  5). 
Surface Morphology ofT Cell Lines.  Because scanning elec- 
tron microscopy served to document substantive cytoarchitec- 
rural defects in the case of WAS blood lymphocytes, this ap- 
proach was applied to the analysis of the T  cell lines.  Calls 
in normal T  cell lines were found to be relatively homoge- 
CD43  CD43 
N2  Irrelevant  L10  T305 
P2 





Figure 5.  Upregulation on activation  of the IL-2R  (CD25) and the T305 
epitope of CD43. The normal cell line N2 and the patient cell lines P2 
and P4, were stained with the indicated mAbs 10 d (resting cells) or 3 d 
after allospecific  stimulation (activated  cells). Similar  results were obtained 
with P5. 
neous in size and morphology and, like normal blood lym- 
phocytes, virtually all cells exhibit a dense surface display of 
microviUus projections  (Fig.  6).  WAS  T  cell lines,  on  the 
other hand, are heterogeneous in size and morphology (Fig. 7 
A) and are abnormal in two respects (Fig. 7, A-D). Although 
some cells exhibit normal lymphocyte surface morphology, 
a large number of cells in each sample show the paucity of 
microvillus  surface projections  previously documented  for 
WAS PBLs. In addition,  some WAS cells have qualitatively 
abnormal  surface projections that  are bulbous  or lamellar; 
other cells have elongated or otherwise irregular shapes. These 
cells with qualitatively abnormal cytoarchitecture have not 
been detected in WAS peripheral blood cells, and were found 
Figure 6.  Scanning electron micrographs of a T cell line from a normal individual. Cells are homogeneous in size and morphology with the surfaces 
of most ceils showing a dense display of microvilhs projections. The micrographs shown are representative  of four normal cell lines examined (N1, 
N2, N3, and N5). The normal cell lines are indistinguishable from normal blood lymphocytes (Reference  5, comparison not shown). Bars =  5 #m. 
871  Molina  et al. Figure 7.  Scanning electron micrographs of WAS patient T ceU lines. The patient ceUs show heterogeneous morphology (A). Some cells are spherical 
with a display of surface microvillus projections (A-C). Other cells have relatively smooth surfaces depleted of microviUi (A-C) or show qualitatively 
abnormal projections that are blunted, bulbous, or lamellar (A-C). Still other cells in the patient population have elongated shapes (B,  C, and D). 
The micrographs shown are representative  of three WAS cell lines examined  (P1, P2,  and PS). Bars, 5 #m. 
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vious differences were noted between WAS resting and prolifer- 
ating cell lines (not shown). 
Discussion 
A panel of long-term allospecific T  cell lines from WAS 
patients and normal individuals has been maintained in cul- 
ture for longer than 3 too. The rationale for establishing pa- 
tient cdl lines was the anticipation that the cells would (a) 
express the inherited abnormal gene product and the immediate 
or early abnormalities resulting from that product, and (b) 
be free of some secondary abnormalities generated in vivo 
when defective cells circulate in the blood.  Following this 
rationale, cell lines,  particularly nontransformed cell lines, 
should offer a simplified experimental system in which to study 
early defects resulting from the inherited defective gene. The 
normal and patient cell lines exhibit the phenotype charac- 
teristic of T lineage cells, being positive for CD2, CD3, TCR- 
c~/~ HLA-class I, CDlla, and CD43, and undergo vigorous 
proliferation when challenged with allostimulant or with PMA 
plus ionomycin. The cells are Ib2-dependent for long-term 
growth, and no spontaneous transformation has been detected. 
Flow cytometry and Western blots showed that surface 
density and molecular weight of CD43 are not detectably 
different in WAS and normal T cell lines. The WAS cell lines 
differ in this respect from WAS blood lymphocytes, previ- 
ously shown to be deficient in CD43 (7-10, 27) and to ex- 
press abnormal molecular weight CD43 isoforms in some 
patients (3 of 8 patients [7], and 10 of 12 [9]). The presence 
of CD43 abnormalities in WAS blood lymphocytes and their 
absence in WAS T  cell lines suggest that these defects are 
not an early pathological event in the WAS. One possible 
explanation is that CD43 defects are generated in the circula- 
tion (4). 
On the other hand, scanning electron microscopic evalu- 
ation demonstrated that the cytoarchitecture of WAS T cell 
lines differs from normal T call lines.  The cytoarchitectural 
abnormalities found in the WAS T  call lines include those 
previously documented in WAS blood lymphocytes. In both 
cases, the dense display of slender surface microvillus projec- 
tions that characterize normal blood lymphocytes and normal 
T cell lines are diminished in number and size. For the case 
of blood lymphocytes, the mean morphology score, which 
quantifies microvilli, is 3.62  _+ 0.22 for normal individuals 
and 2.89  _+ 0.27 for 18 WAS patients (p <.001, [5]). Indeed, 
the paucity of blood lymphocyte surface microvilli, since it 
is consistently found in WAS patients and is specific to the 
disease, has proved useful as a criterion for diagnosis in difficult 
cases (5). The cytoarchitectural defects in the T cell lines from 
WAS patients were found to be more extensive than the defects 
of WAS blood lymphocytes, since they include qualitative 
abnormalities in addition to the paucity of microviUi.  The 
findings of cells with qualitatively defective cytoarchitecture 
in the WAS T cell lines, but not in WAS patient blood, may 
reflect mechanisms that remove qualitatively defective cells 
from the circulation. 
The documentation in WAS T cell lines of abnormal cytoar- 
chitecture as previously shown in WAS blood lymphocytes 
verifies that the inherited defective gene is expressed in the 
T cell lines. It is not known whether the paucity of microvilli 
detected by scanning electron microscopy has an exact corre- 
late in the living cells, or only a related correlate. It is pos- 
sible that the absence of microvilli results from the action 
of the scanning electron microscopy cell fixing procedure in 
combination with an underlying cellular defect in the WAS 
patients' cells. Nonetheless, the findings strongly indicate an 
underlying defect in cell cytoarchitecture or its regulation. 
This study thus shows that cytoarchitecture is profoundly 
defective in T  cell lines from WAS patients.  On the other 
hand, expression of a multitude of cell surface molecules in- 
cluding CD43,  as well as proliferative responses to specific 
allostimulant and mitogen, are normal in the WAS T  cell 
lines. The expression of the cytoarchitectural defect in WAS 
cell lines maintained in an environment free of the pathode- 
gradative events that occur in the circulation strongly sug- 
gests that the generation of the cytoarchitectural defects is 
an early pathogenic event in this disease, and is closely linked 
to the inherited primary defect. The cumulative findings sug- 
gest that the gene that is defective in WAS patients encodes 
a protein that normally functions to maintain or regulate the 
cytoskeletal structure of blood cells. 
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